- RecruitingHuman Pharmacology (Phase I)- Other
Phase IB clinical trial to assess the safety, tolerability, and preliminary efficacy of AloCELYVIR (Mesenchymal allogenic cells + ICOVIR-5) in children, adolescent and young adults with newly diagnosed diffuse intrinsic pointine glioma (DIPG) in combination with radiotherapy or medulloblastoma in relapse/progression in monotherapy.
This study is testing a new treatment called AloCelyvir for children and young adults with two types of brain cancer: newly diagnosed DIPG or medulloblastoma that has returned. It's looking to see if the treatment is safe and what effects it might have.
For: Newly diagnosed Diffuse Intrinsic Pointine Glioma (DIPG) or Medulloblastoma in relapse/progression in children, adolescents and young adults.Spain - RecruitingPhase I and Phase II (Integrated)- Other
Phase I/II stUdy of ALoCelyvir in patientS with mEtastaticUveal Melanoma (PULSE-UM)
This study is looking at a new treatment called AloCelyvir for people with a type of eye cancer that has spread. It's an early stage study to see if the treatment works and how safe it is. Doctors will measure if tumours shrink and how long people live.
For: mEtastatic Uveal MelanomaSpain - AuthorisedHuman Pharmacology (Phase I)- Other
Feasibility clinical trial of the combination of AloCelyvir with chemotherapy and radiotherapy for the treatment of children and adolescents with relapsed or refractory extracranial solid tumors.
This study looks at a new treatment called AloCelyvir, combined with usual chemotherapy and radiotherapy, for young people (aged 18 and older) with cancer outside the brain that has come back or not responded to previous treatments. It aims to find the safest dose.
For: Relapsed or refractory extracranial solid tumors in children and adolescents.Spain